Saturday 17 October 2026
Export BOLT’s income statement to Excel — free account
Bolt Biotherapeutics, Inc.
BOLT Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.7%, EPS fell 2.47%, free cash flow grew 38.9% and total debt fell 14.3%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
4.06
0.18
−4.25%
Follow BOLT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 4 | 1 |
+8 more TTM periods Free account |
| (111.65%) | (88.79%) | (79.75%) | (81.97%) | ||
| (49.62%) | (44.19%) | (42.69%) | (48.95%) | ||
ROIC |
(143.75%) | (122.80%) | (119.22%) | (141.48%) | |
Return on Tangible Assets |
(216.60%) | (152.07%) | (144.67%) | (157.26%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(18.23) | (20.56) | (20.83) | (24.09) | |
Free Cash Flow |
(30.82) | (34.55) | (38.96) | (46.23) | |
Capital Expenditures |
0.63 | (0.04) | 0.89 | 0.89 | |
| Other line items | |||||
Cash ROIC |
(62.93%) | (55.49%) | (52.41%) | (53.96%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
457.47% | 366.98% | 370.80% | 678.86% | |
Selling, General and Administrative Expense of Revenue |
248.38% | 196.46% | 179.27% | 281.52% | |
Share Based Compensation of Revenue |
54.15% | 40.28% | 36.15% | 56.27% | |
Operating CF/Net income |
1.09 | 1.17 | 1.19 | 1.10 | |
Depreciation/Fixed assets |
0.89 | 0.57 | 0.50 | 0.43 | |
Capex/Depreciation |
1.25 | (0.07) | 1.43 | 1.38 | |
Revenue per Share |
2.78 | 3.87 | 4.12 | 2.71 | |
Operating CF per Share |
(18.60) | (20.54) | (21.31) | (24.56) | |
Capex per Share |
0.37 | (0.02) | 0.48 | 0.46 | |
Capex to Sales |
(0.13) | 0.01 | (0.12) | (0.17) |
Columns are period end dates